FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2018/11/016365 [Registered on: 16/11/2018] Trial Registered Prospectively
Last Modified On: 04/04/2022
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   To assess the Safety and efficacy of clingen vaginal suppositories in patients with mixed vaginal infection 
Scientific Title of Study   A phase IV,double blind,comparative,Prospective,Multicentric study to assess safety and efficacy of fixed dose combination of clindamycin 100 mg and Clotrimazole 100 mg Vaginal suppositories (clingen) VS. Clotrimazole 100 mg vaginal suppositories in patients with mixed vaginal infection" 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
AZ-C-ZIR-15-101 Version No.01 Dated 29th Nov 2016  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Manish Maladkar 
Designation  Sr. Vice President Medical & Regulatory 
Affiliation  Aristo Pharmaceuticals Pvt Ltd 
Address  Aristo Pharmaceuticals Pvt Ltd 23A Shah Industrial Estate off Veera Desai Road Andheri West Mumbai

Mumbai (Suburban)
MAHARASHTRA
400053
India 
Phone  09820432880  
Fax    
Email  drmaladkar@outlook.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Shrikant Patil 
Designation  asst GM 
Affiliation  Aristo Pharmaceuticals Pvt Ltd 
Address  Aristo Pharmaceuticals Pvt Ltd 23A Shah Industrial Estate off Veera Desai Road Andheri West Mumbai

Mumbai (Suburban)
MAHARASHTRA
400053
India 
Phone  09819304787  
Fax    
Email  shrikant.patil@aristopharma.org  
 
Details of Contact Person
Public Query
 
Name  Manisha Banavalikar 
Designation  GM Clinical Research 
Affiliation  AnaZeal Analyticals & Research Pvt Ltd 
Address  AnaZeal Analyticals & Research Pvt Ltd D 334 TTC Industrial Area MIDC Turbhe Navi Mumbai India

Mumbai (Suburban)
MAHARASHTRA
400705
India 
Phone  09892166748  
Fax    
Email  manishab@anazeal.com  
 
Source of Monetary or Material Support  
Aristo Pharmaceuticals Pvt Ltd 
 
Primary Sponsor  
Name  Aristo Pharmaceuticals Pvt Ltd 
Address  23 A,Shah Industrial Estate Off Veera Desai Road Andheri West Mumbai-400053 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 4  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DrSunesh Kumar  All india Institute of medical Sciences  All india Institute of medical Sciences Ansari nagar New Delhi-110029
New Delhi
DELHI 
26594579

Kumar.sunesh@yahoo.com 
Dr Dattatray Sonwalkar  KMRFS NIKOP HOSPITAL  Ring road phaltan satara
Satara
MAHARASHTRA 
9423262300

nikophospital59@gmail.com 
Dr Kirankumar Nale  KMRFS NIKOP HOSPITAL  Ring road phaltan satara
Satara
MAHARASHTRA 
9822037374

nikophospital59@gmail.com 
DrDeepa Kala  Terna Speciality Hospital  Plot no. 12,Sec-22,Opp.Nerul Railway Station, Nerul (West),Navimumbai-400706.
Thane
MAHARASHTRA 
9820503082

dkala24@yahoo.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 4  
Name of Committee  Approval Status 
Institute Ethics Committee AIIMS, New Delhi, India  Approved 
KMRFs Nikop institutional Ethics Committe  Approved 
KMRFs Nikop institutional Ethics Committe  Approved 
Terna Ethics Committee, Nerul   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N760||Acute vaginitis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Clotrimazole 100mg  HS for 7 days  
Intervention  FDC of CLINDAMYCIN 100 mg and Clotrimazole 100 mg   HS for 7 days  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Female 
Details  1.Females 18 years of age or older.
2.Women with regular menstruation and visiting the trial centre from 5th day to 20th day of the cycle or post menopausal women (defined as women with absence of menstruation for at least 1 year from the date of screening.), or women with surgical menopause (oophorectomy, hysterectomy).
3. Female subjects screened positive for mixed vaginal infection based on two or more of the following microscopic findings
1) Yeasts or pseudohyphae on wet preparation (40 – 60% sensitivity) of vaginal discharge. – and/or Yeasts or pseudohyphae on Gram stain (up to 65% sensitivity) of vaginal discharge
2) Direct observation of the organism (T. vaginalis) by a wet smear (normal saline) or acridine orange stained slide from the posterior vaginal fornix (sensitivity 40-70% cases).
3) A Gram stain slide with Nugent score more than equal to 4.
And/or
(Amsel’s Diagnostic Criteria for Bacterial Vaginosis)
a) Off-white, thin, homogeneous discharge with little if any inflammation.
b) pH of vaginal fluid greater than 4.5, using pH paper that measures from 4.0 to 6.0
c) Positive whiff test for amine odour after addition of 10% KOH.
d) More than or equal to 20% Clue cells of the total epithelial cells on microscopic examination of the saline/wet mount.
4. Subjects who agree to refrain from the use of intra-vaginal products throughout the study (e.g., douches, feminine deodorant sprays, Spermicides, tampons, and diaphragms).
5. Capable of giving written informed consent.
6. Agree to no intercourse for 8 days from the day of start of treatment.
 
 
ExclusionCriteria 
Details  1. Pregnant or lactating women.
2. Patients receiving neuromuscular blocking agents.
3. Patients having history of hypersensitivity to Clindamycin or Clotrimazole.
4. Patients with history of regional enteritis, ulcerative colitis, pseudo-membranous colitis or history
of antibiotic associated colitis.
5. Women receiving any antibiotic treatment 14 days prior to enrolment.
6. Female patient of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy.
7. Patients who have participated in any clinical trial in the past 3 month.
8. History of significant cardiovascular disorders or primary or secondary immunodeficiency.
9. Any other condition that in the opinion of the Investigator does not justify the patient’s participation in the study.
10. Presence of vaginal / vulval ulcer or any other vulval, vaginal or medical condition, including cervical neoplasia/ treatment that might confound treatment response.
11. Inability to keep return appointments
12. Presence of intrauterine device.
13. Patients who do not agree to stop use of any other antibacterial, antifungal or anti protozoal drug during trial period.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
• The primary efficacy endpoint is the therapeutic cure which requires both clinical cure and pathogen eradication confirmed by microbiological vaginal swab testing and Nugent score of 0-3 at last visit.
• Safety endpoints (adverse events, vital signs).
 
visit 1 visit 2 visit 3 visit 4 
 
Secondary Outcome  
Outcome  TimePoints 
• The secondary efficacy endpoints are
a) Time to resolution of symptoms.
b) Change in lab parameters compared to baseline. (CBC, ESR, LFT(SGPT (ALT), SGOT (AST), S. Bilirubin (TOTAL), S. Bilirubin (DIRECT), RFT (Serum Creatinine, BUN) , urine routine and microscopic and BSL (Random). 
Visit 1 and Visit 4 
 
Target Sample Size   Total Sample Size="300"
Sample Size from India="300" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   22/11/2018 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="6"
Days="1" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   None yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

Vaginitis is an inflammation of the vagina. One third of women will have symptoms of Vaginitis. It affects women’s of all ages but is most common during the reproductive years. A change in balance of the yeast and bacteria that normally live in the vagina can result in vaginitis. This causes lining of vagina to become inflamed. Factors that can change the normal balance of vagina include: Use of antibiotics, Change in hormone level due to pregnancy, breastfeeding or menopause, douching, spermicides, sexual intercourse and infection. Treatment will depend on the cause of vaginitis. Treatment may be either with pill or a cream or a gel that is applied to vagina. Bacterial vaginitis is caused by overgrowth of bacteria that occur naturally in vagina main symptom is increased discharge with strong fishy odour the discharge usually is thin and dark or dull gray but may have a greenish color. Itching is not common but may be present if there is lot of discharge. Several different antibiotics can be used to treat Bacterial Vaginosis. One of them is Clindamycin.

A yeast infection is caused by fungus called Candida. It is found in small numbers in the normal vagina. However when the balance of the bacteria and yeast in the vagina is adhered, the yeast may overgrow and causes symptoms. Use of some type of antibiotics increases your risk of yeast infection. The antibiotics kill natural vaginal bacteria, which keeps yeast in check. The yeast can then overgrow. Most common symptoms of yeast infection are itching and burning of the area outside the vagina called vulva. The vulva may be red and swollen. The vaginal discharge is usually white, lumpy and has no odour. Some women with yeast infection notice an increase or change in discharge. Trichomoniasis is condition caused by microscopic parasite Trichomonas vaginalis. it is spread through sex. Signs may include a yellow gray or green vaginal discharge. The discharge may have fishy odour. There may be burning, Irritation, redness and swelling of vulva. Sometimes there is pain during urination.

Clindamycin is an antibacterial agent, kills bacteria by inhibiting bacterial protein synthesis by affecting the process of peptide chain initiation. Clindamycin has excellent activity against many anaerobes as well as aerobic gram-positive Cocci. It exhibits anti bacterial activity against most of the organisms that that have been associated with bacterial5.

Clotrimazole is an imidazole with broad spectrum antifungal action it inhibits fungal cell wall synthesis by inhibiting synthesis of ergosterol, an important component of cell wall which alters the permeability of cell membrane of sensitive fungi and leads to structural and functional impairment of the cyctoplasmic membrane. Clotrimazole has fungicidal action against Candida albicans and trichomonocidal action5.

 

Clingen suppositories are available in India by Aristo Pharmaceuticals for last 10 years. Periodic safety and efficacy of the fixed dose combination is to be assessed. Clingen is indicated in mixed vaginal infections including Bacterial Vaginosis, Vaginal Candidiasis, Trichomoniasis; infective leucorrhea and non-specific vaginitis. The aim of the present study is to generate safety and efficacy data of Clingen suppositories in clinical condition of mixed Vaginitis in Indian population over a single drug treatment of clotrimazole suppositories. This Clinical Study is “A phase IV, double blind, prospective, comparative, randomized, multicentric study to assess safety and efficacy of fixed dose combination of Clindamycin (100 mg) and Clotrimazole (100 mg) vaginal suppositories (Clingen) compared to clotrimazole (100 mg) vaginal suppositories in patients with mixed vaginitis.” proposed to be conducted in the Indian population as per the requirement of schedule Y of Drugs & Cosmetic rules 2005, under the NOC of Drugs Controller General of India (DCGI), for retaining permission of Manufacturing & Marketing of Clingen suppositories  in India

 
Close